# A Study of Mavrilimumab Versus Anti Tumor Necrosis Factor in Subjects With Rheumatoid Arthritis

> **NCT01715896** · PHASE2 · COMPLETED · sponsor: **MedImmune LLC** · enrollment: 215 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **BIOLOGICAL:** Golimumab 50 mg
- **BIOLOGICAL:** Mavrilimumab 100 mg

## Key facts

- **NCT ID:** NCT01715896
- **Lead sponsor:** MedImmune LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-03
- **Primary completion:** 2014-11
- **Final completion:** 2015-02
- **Target enrollment:** 215 (ACTUAL)
- **Last updated:** 2016-10-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01715896

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01715896, "A Study of Mavrilimumab Versus Anti Tumor Necrosis Factor in Subjects With Rheumatoid Arthritis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01715896. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*